ESTRO 2025 - Abstract Book

S1990

Clinical - Urology

ESTRO 2025

Six (12%) patients developed distant metastasis after a median time of 30 months (IQR 17-49). 5- year MFS was 88.5%. No acute G3-4 toxicities were reported. Only one late G3 GU toxicity was reported (dysuria).

Conclusion: SBRT delivered to prostate and seminal vesicles in 5-7 fx represents a safe treatment for HR clinically localized HRPCa. This analysis shows there is a cohort of HRPCa patients who may benefit from local SBRT without lymph nodal elective irradiation. Further studies are needed to validate these findings

Keywords: High-risk Prosate Cancer, SBRT

2233

Digital Poster MRI-dose-adapted hypofractionated salvage RT (Hypo-sRT) for prostate bed macroscopic recurrence: Acute toxicities from a mono-institutional study Gianluca Vullo 1 , Giuseppe Facondo 1 , Marco Andrea Signor 1 , Francesca Titone 1 , Eugenia Moretti 2 , Sara Bassi 2 , Marco Trovò 1 1 Radioterapia Oncologica, ASUFC, Udine, Italy. 2 Fisica Sanitaria, ASUFC, Udine, Italy Purpose/Objective: We aim to report and acute toxicity profile and early biochemical outcomes from a series of pts diagnosed with prostate bed recurrence and treated with a MRI-dose-adapted Hypo-sRT schedule.

Material/Methods: We analysed data from 8 pts diagnosed with macroscopic prostate bed recurrence after radical prostatectomy for